Kimia Biosciences Ltd. engages in the manufacture and distribution of pharmaceutical products. The company is headquartered in New Delhi, Delhi. The company went IPO on 2016-03-21. The firm provides its products under various categories: active pharmaceutical ingredients (APIs), intermediates and formulations. The firm's commercial products include acotiamide hydrochloride hydrate, azelnidipine, benfotiamine, benidipine hydrochloride, citicoline sodium, gliclazide, levosulpiride, luliconazole, oxaceprol, prucalopride succinate, teneligliptin hydrobromide hydrate, vildagliptin, fimasartantrihydrate potassium, obeticholic acid and ursodeoxycholic acid.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.